<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03327792</url>
  </required_header>
  <id_info>
    <org_study_id>2000021703</org_study_id>
    <nct_id>NCT03327792</nct_id>
  </id_info>
  <brief_title>Mavoglurant in Alcohol Drinking</brief_title>
  <official_title>A Pilot Study on the Safety and Efficacy of Mavoglurant in Alcohol Drinking</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this alcohol-interaction pilot study is to provide information on the effect&#xD;
      of mavoglurant on the pharmacokinetics of alcohol and on alcohol responses, including&#xD;
      stimulation, sedation, intoxication, body sway and physiological responses. The investigators&#xD;
      propose to test the effects of 200 mg mavoglurant versus placebo on alcohol related&#xD;
      responses. This is a between subjects double blind randomized design in which the&#xD;
      investigators plan to run 40 subjects to obtain 28 completers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this alcohol-interaction pilot study is to provide information on the effect&#xD;
      of mavoglurant on the pharmacokinetics of alcohol and on alcohol responses, including&#xD;
      stimulation, sedation, intoxication, body sway and physiological responses. The investigators&#xD;
      propose to test the effects of 200 mg mavoglurant versus placebo on alcohol related&#xD;
      responses. This is a between subjects double blind randomized design in which the&#xD;
      investigators plan to run 14 subjects to obtain 10 completers.&#xD;
&#xD;
      Subjects will participate in two lab sessions, one prior to taking medication and one&#xD;
      following 7-10 days of mavoglurant/placebo. During each session, participants will receive&#xD;
      successive doses of alcohol over a 90 min period designed to raise their blood alcohol levels&#xD;
      to 80 mg/dl; this dose was chosen because this is close to the legal limit of intoxication&#xD;
      and to the peak BAC the investigators have observed in prior research studies. Subjects will&#xD;
      be monitored throughout the lab session and will receive a phone call two days following the&#xD;
      2nd lab session and a follow-up appointment one week after the 2nd lab session to assess any&#xD;
      remaining side effects from the medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 7, 2018</start_date>
  <completion_date type="Anticipated">July 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abnormal Labs and Adverse Events</measure>
    <time_frame>Day 10</time_frame>
    <description># of participants with abnormal lab values or adverse events related to the interaction of alcohol and mavoglurant</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Alcohol Drinking</condition>
  <arm_group>
    <arm_group_label>200 mg Mavoglurant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg mavoglurant once daily for 7-10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo once daily for 7-10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mavoglurant</intervention_name>
    <description>200 mg Mavoglurant</description>
    <arm_group_label>200 mg Mavoglurant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Ages 21-50&#xD;
&#xD;
          2. Able to read English at 6th grade level or higher and to complete study evaluations&#xD;
&#xD;
          3. Social drinkers&#xD;
&#xD;
          4. Willing to abstain from drinking alcohol during the outpatient study medication&#xD;
             treatment period&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Seeking treatment for alcohol drinking&#xD;
&#xD;
          2. Current DSM-V criteria for any other substances, other than alcohol or nicotine.&#xD;
&#xD;
          3. Positive test results at any appointments after the initial intake appointment on&#xD;
             urine drug screens conducted for opiates, cocaine, marijuana, benzodiazepines and/or&#xD;
             barbiturates.&#xD;
&#xD;
          4. Regular use of psychoactive drugs including anxiolytics and antidepressants.&#xD;
&#xD;
          5. Psychotic or otherwise severely psychiatrically disabled.&#xD;
&#xD;
          6. Any medical conditions (including hepatic and renal impairment) that would&#xD;
             contraindicate the consumption of alcohol or administration of mavoglurant.&#xD;
&#xD;
          7. History of neurological trauma or disease, delirium, or hallucinations, or any&#xD;
             significant systemic illness or unstable medical condition.&#xD;
&#xD;
          8. Women who are pregnant, nursing, or refuse to use a reliable method of birth control.&#xD;
             Urine pregnancy tests will be completed at intake and prior to administration of&#xD;
             alcohol at each lab session.&#xD;
&#xD;
          9. Subjects who report disliking spirits will be excluded because hard liquor will be&#xD;
             provided during the alcohol administration.&#xD;
&#xD;
         10. Subjects who have taken any investigational drug and/or participated in another study&#xD;
             which involves additive blood sampling and/or interventional measures that would be&#xD;
             considered excessive in combination with the current protocol within 4 weeks&#xD;
             immediately preceding admission to the treatment period.&#xD;
&#xD;
         11. Subjects who report any daily drug use during the 30 days prior to randomization for&#xD;
             the following: anxiolytics, beta blockers, central nervous system stimulants,&#xD;
             hypnotics, non-therapeutic doses of neuroleptics and antidepressants, drugs with&#xD;
             psychotropic activity or drugs which cause excessive sedation.&#xD;
&#xD;
         12. Subjects who have donated blood within the past six weeks.&#xD;
&#xD;
         13. Subjects who have taken, within the prior 14 days, the following strong inhibitors or&#xD;
             inducers of CYP1A, CYP2C, and CYP3A and CYP3A4: ciprofloxacin, enoxacin, fluvoxamine;&#xD;
             gemfibrozil; fluconazole, fluvoxamine, ticlopidine; boceprevir, clarithromycin,&#xD;
             conivaptan, grapefruit juice, indinavir, itraconazole, ketoconazole,&#xD;
             lopinavir/ritonavir, mibefradil, nefazodone, nelfinavir, posaconazole, ritonavir,&#xD;
             saquinavir, telaprevir, telithromycin, voriconazole; bupropion, fluoxetine,&#xD;
             paroxetine, quinidine; avasimibe, carbamazepine, phenytoin, rifampin, and St. John's&#xD;
             wort. We will also exclude individuals who have taken, within 14 days, the following&#xD;
             moderate inhibitors and inducers of CYP3A: Amprenavir, aprepitant, atazanavir,&#xD;
             ciprofloxacin, crizotinib, darunavir/ritonavir, diltiazem, erythromycin, fluconazole,&#xD;
             fosamprenavir, imatinib, and verapamil; and bosentan, efavirenz, etravirine,&#xD;
             modafinil, and nafcillin.&#xD;
&#xD;
         14. Current use of warfarin.&#xD;
&#xD;
         15. Use of any medications that are contraindicated with mavoglurant and alcohol.&#xD;
&#xD;
         16. AST, ALT, total bilirubin &gt;1.5 times upper normal; serum creatinine, &gt;2 times upper&#xD;
             normal limit, total bilirubin&gt;1.5 times ULN; Serum creatinine &gt;2.0 times ULN.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suchitra Krishnan-Sarin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor of Psychiatry</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nick Franco</last_name>
    <phone>203-974-7679</phone>
    <email>nicholas.franco@yale.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dana Cavallo</last_name>
    <phone>203-974-7607</phone>
    <email>dana.cavallo@yale.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CMHC, Substance Abuse Center</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06519</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana A Cavallo, Ph.D.</last_name>
      <phone>203-974-7607</phone>
      <email>dana.cavallo@yale.edu</email>
    </contact>
    <contact_backup>
      <last_name>Nick Franco</last_name>
      <phone>2039747607</phone>
      <email>nicholas.franco@yale.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Suchitra Krishnan-Sarin, Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>October 27, 2017</study_first_submitted>
  <study_first_submitted_qc>October 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2017</study_first_posted>
  <last_update_submitted>June 10, 2021</last_update_submitted>
  <last_update_submitted_qc>June 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Suchitra Krishnan-Sarin</investigator_full_name>
    <investigator_title>Professor of Psychiatry</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alcohol Drinking</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

